patent.fyi
Applications  /  US 2026/0356854
United States Patent Application Publication

US 2026/0356854 A1

Published
Nov 12, 2026
Filed
Nov 1, 2023
Earliest date on the face
Nov 4, 2022
Classification
C07D 519/00
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Oxidative cleavage of an alkyl group

What ifWhat if a benzyl group masked the bridged nitrogen and oxidative cleavage released the secondary amine?
Claim language“is (R)-6-methyl-1-((6R,10S)-6,7,9,10-tetrahydro-8H-6,10-methanoazepino[4,5-g]quinoxalin-8-yl)-1,3-dihydrofuro[3,4-c]pyridin-7-ol”

A benzyl group attaches to the bridged nitrogen through a methylene carbon. Oxidation at that carbon forms a carbinolamine that fragments into the secondary amine and benzaldehyde.

1.1Free base nanocrystal suspension

What ifWhat if a suspension of free base nanocrystals provided the dosage form?
Claim language“a pharmaceutically acceptable salt thereof”

Wet media milling reduces free base crystals to a submicrometer size in water containing a nonionic surfactant. The surfactant limits aggregation, and the smaller particles provide more surface area for dissolution.

1.1Cyclodextrin inclusion of neutral pyridone

What ifWhat if a neutral pyridone form associated with cyclodextrin in a nonionic inclusion complex?
Claim language“pharmaceutically acceptable salt of a tautomer thereof”

Hydroxypropyl beta cyclodextrin provides a hydrophobic cavity and a water-compatible exterior. The cavity associates reversibly with a hydrophobic portion of the neutral molecule, and dilution shifts the equilibrium toward free compound.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Amine masking in analytical training

An analytical chemistry training laboratory uses the fused heterocyclic prodrug and its parent amine as a paired set of reference materials. Separate vials hold each compound and a mixture containing both. Learners inject the vials into a liquid chromatograph coupled to a mass spectrometer and assign the peaks using retention times and mass spectra from the individual reference materials.

Component substitution

Lactate salt in place of hydrochloride

A monolactate salt supplies the counterion in place of chloride in a hydrochloride preparation of the same prodrug. A solution of the isolated free base in ethanol receives one molar portion of L-lactic acid per molar portion of prodrug. The solvent is removed under reduced pressure, and quantitative proton nuclear magnetic resonance measures the molar ratio of lactate to prodrug in the recovered material.

Parameter or scale variation

Microscale buffer stability time course

A sealed 96-well plate holds 100 microliters per well of 10 micromolar prodrug in 50 millimolar phosphate buffer at pH 7.4. The plate incubates at 37 °C, with three dedicated wells sampled at each of 0, 15, 30, 60, and 120 minutes. Each sample is diluted immediately with an equal volume of chilled acetonitrile and analyzed by liquid chromatography against separate prodrug and parent amine calibration solutions.

Combination with existing systems

Prodrug release through a flow cell

A compact containing the prodrug and microcrystalline cellulose sits on a mesh support inside a temperature-controlled flow-through dissolution cell. A pump delivers pH 6.8 phosphate buffer at 37 °C through the cell at 8 milliliters per minute. A fraction collector captures the effluent at five-minute intervals, and liquid chromatography measures the prodrug and parent amine in each fraction.

Prodrug monitoring in a dialysis cell

A two-chamber equilibrium dialysis cell holds a solution of the prodrug in buffered human serum albumin on the donor side and matching buffer on the receiver side. A regenerated cellulose membrane with a nominal 10 kilodalton cutoff separates the chambers and retains the albumin. Liquid chromatography with mass spectrometry measures the intact prodrug and released parent amine in both chambers, and the receiver-to-donor concentration ratio estimates the unbound fraction of intact prodrug when serial samples show stable concentrations.

Automated or data-driven variant

Automated kinetic fitting from chromatograms

A thermostated autosampler injects replicate prodrug solutions at scheduled times and sends the chromatograms to a data-processing script. The script integrates the prodrug and parent amine peaks in retention windows defined by separate reference injections and converts the areas to concentrations using calibration curves. It fits the prodrug concentrations to a first-order decay model and reports the apparent half-life and fit residuals for each incubation condition.

Specific version of a part

Crystalline methanesulfonate form

Methanesulfonic acid transfers a proton to a basic nitrogen in the compound. The resulting cations and methanesulfonate anions form an ionic solid.

Neutral pyridone tautomer

A proton transfers formally from the position 7 hydroxyl oxygen to the adjacent pyridine nitrogen. The ring bond pattern shifts to give a carbonyl at position 7 and an N–H bond.

Cite aspatent.fyi, US 2026/0356854 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356854/, SHA-256 5386bb7454bfa4b505d82e2ba0b1d392ed54abd21edac40681ca7aa4b0745b2c
First published
Permanent addresshttps://patent.fyi/US20260356854/
Content fingerprint (SHA-256)5386bb7454bfa4b505d82e2ba0b1d392ed54abd21edac40681ca7aa4b0745b2c
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi